U.S. FDA approves Ryeqo to treat menorrhagia related to uterine fibroids in premenopausal women!

Pfizer and Myovant Sciences jointly announced on May 29, 2021 that the U.S. Food and Drug Administration (FDA) has approved (relugolix 40 mg, estradiol 1.0 mg, norethindrone acetate 0.5 mg). The drug is a combination tablet of relugolix. It is the first once-daily drug to treat uterine fibroid-related menorrhagia (HMB) in premenopausal women. The treatment duration can be up to 24 months.

Ryeqo is an oral non-peptide gonadotropin-releasing hormone receptor antagonist. Japan's Takeda Pharmaceutical Company has collaborated with Japan's ASKA Pharmaceutical Company and the British Myovant Technology Biopharmaceutical Company to develop Ryeqo for the treatment of uterine fibroids, endometriosis, prostate cancer and other indications. Among them, the treatment of uterine fibroids and endometriosis was approved for marketing in Japan on January 8, 2019. The U.S. FDA approved the market on December 8, 2020, for the treatment of prostate cancer.

In the clinical treatment of uterine fibroids, common adverse reactions include: uterine bleeding, hyperhidrosis, genital bleeding, increased alanine aminotransferase (ALT), fatigue, liver function damage, menorrhagia, headache, hot flashes, constipation, diarrhea, increased blood sugar, decreased hemoglobin, increased triglycerides, increased aspartate aminotransferase (AST), depression, musculoskeletal pain, etc.

Finally, the editor of Medical Companion Travel hopes that patients who are currently using Ryeqo will not believe or spread rumors. Currently, there is a lot of unreliable information on the Internet that conveys wrong information to everyone. For example, increasing the dose of the drug can double the therapeutic effect, or reducing the dose of the drug can avoid side effects. These are without any basis. Only by following the doctor's instructions can the drug itself be used to its maximum effect.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.